Pharma Deals Review, Vol 2003, No 36 (2003)

Font Size:  Small  Medium  Large

Novo Nordisk and Fournier Pharma Sign Co-Marketing Agreement for Repaglinide in Europe

Business Review Editor

Abstract


Novo Nordisk entered into a deal with Fournier Pharma to co-market its Repaglinide drug in Europe. The deal has been designed in such a way that Fournier will make a down payment and subsequent sale-dependent royalties to Novo Nordisk.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.